Search Bar & Filters
Found 9 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the safety and effects of a new drug called NNC0487-0111 in people with Heart Failure with preserved Ejection Fraction HFpEF or Heart Failure with mildly reduced Ejection Fraction HFmrEF who also have excess body weight. This study compares NNC0487-0111 against a placebo to determine if it is safe and effective for treating these heart conditions in people with obesity. The study is a randomized, controlled trial conducted by Novo Nordisk AS. Participants will receive either NNC0487-0111 or a placebo by subcutaneous injection once a week. The study drug dose may increase over time for those receiving NNC0487-0111. Treatment assignment is random, and the study includes a parallel design with two groups one receiving the experimental drug and one receiving placebo. The treatment period and monitoring last up to 165 weeks. During the study, participants will be monitored for heart failure events, cardiovascular death, hospital visits related to heart failure, and other major cardiovascular outcomes. They will complete questionnaires about their heart failure symptoms and quality of life. Kidney function will also be assessed in some participants. Safety and effectiveness will be evaluated throughout the study period, which can last over three years, with regular visits for injections and assessments.
Actively Recruiting
Researchers are evaluating camizestrant compared to standard endocrine therapy in patients with ER-positive, HER2-negative early breast cancer who have an intermediate or high risk of disease recurrence. This Phase III open-label study includes patients who have completed definitive locoregional therapy, with or without chemotherapy, and have received standard adjuvant endocrine therapy for at least 2 years and up to 5 years. The study aims to determine if camizestrant improves invasive breast cancer-free survival and other important outcomes over a long-term follow-up. Participants will be randomly assigned to receive either camizestrant orally or continue standard endocrine therapy chosen by their doctor, which may include aromatase inhibitors like exemestane, letrozole, anastrozole, or tamoxifen. Treatment in both groups will last for up to 60 months. The study allows prior use of CDK46 inhibitors and includes an open-label design where both participants and researchers know the assigned treatment. During the study, participants will be monitored with assessments including survival outcomes, disease-free survival, relapse-free survival, and overall survival for up to 10 years from the last patient randomized. Safety will be tracked through adverse event reporting, laboratory and vital signs tests, and symptom questionnaires measuring arthralgia, hot flushes, vaginal dryness, and quality of life. Pharmacokinetics will be studied up to 6 months after treatment starts. The total duration of participation can extend over many years to capture long-term results.
Actively Recruiting
Researchers are studying the effects of orforglipron compared to a placebo in adults aged 50 and older who have atherosclerotic cardiovascular disease ASCVD andor chronic kidney disease CKD. This Phase 3 trial aims to evaluate how orforglipron impacts major cardiovascular events over about five years of participation. Participants will be randomly assigned to receive either orforglipron orally along with standard care or a placebo orally with standard care. The study is double-blind, meaning neither participants nor researchers know who receives the active drug or placebo. This design helps measure the drugs impact on cardiovascular health and kidney function over the study duration. During the study, participants will be monitored regularly to track the time to the first major cardiovascular event and other health outcomes such as kidney function changes and the onset of type 2 diabetes. The study involves ongoing assessments from baseline through the five-year period, including follow-ups to ensure safety and gather detailed health information.
Actively Recruiting
Researchers are investigating the effectiveness of adding liothyronine LT3 to levothyroxine LT4 treatment in patients with autoimmune hypothyroidism who continue to experience severe tiredness despite having normalized thyroid hormone levels on LT4 alone. This study addresses the problem that LT4 monotherapy may not fully replicate the natural balance of thyroid hormones, as healthy individuals produce some T3 directly. The trial also explores whether certain genetic factors influence response to combination therapy. The study begins with a run-in period where all participants switch to a standardized generic LT4 to stabilize thyroid hormone levels. After confirming normal TSH levels and persistent tiredness, participants enter a one-year randomized, double-blind trial comparing LT4LT3 combination therapy to LT4 with placebo. The LT4LT3 group takes LT4 once daily and LT3 twice daily at a set ratio. Visits occur at baseline and multiple times over the year to adjust doses and monitor health. Participants undergo physical exams, ECGs, blood tests, and complete questionnaires about tiredness, quality of life, and medical resource use throughout the study. Additional measures include bone markers, scans, cardiovascular and metabolic assessments, and neurocognitive tests in subgroups. The main outcome is the change in tiredness scores over 52 weeks, with safety and genetic factors also evaluated. The total study duration includes the run-in and treatment phases, lasting several months to over a year.
Actively Recruiting
Researchers are studying women with node-positive breast cancer who receive neoadjuvant systemic therapy NST, which includes chemotherapy with or without immunotherapy. The study aims to understand the safety and quality of life effects of using less invasive methods compared to more invasive axillary staging and treatment after NST. This is important because patients whose lymph nodes show no remaining cancer after NST may not benefit from extensive lymph node removal, but more evidence is needed about the safety and impact of less invasive approaches. This multicenter observational study collects detailed information on patients treated with NST for node-positive breast cancer. It gathers data about the cancer, staging methods before and after NST, and treatment details from medical records. Patients complete questionnaires about their quality of life at diagnosis, and then 1 and 5 years later. The study database is maintained by the Netherlands Cancer Registry and aims to inform future treatment guidelines. Participants provide information through patient-reported outcome measures and undergo regular clinical follow-up to monitor disease-free survival, breast cancer-specific survival, overall survival, and rates of cancer recurrence in the lymph nodes over five years. Quality of life is assessed using several validated tools at baseline and during follow-up. The study results will help balance treatment decisions between less and more invasive options and support shared decision making for women with this breast cancer type.
Actively Recruiting
Researchers are investigating how various factors beyond tumor stage, such as biochemical, histopathological, genomic, environmental, and clinical characteristics, affect the outcomes of patients diagnosed with colorectal cancer CRC, small bowel cancer, and anal cancer. This observational study aims to collect detailed information from diagnosis through long-term follow-up to better understand prognosis and treatment effects in both early and late-stage cancers. The study addresses the gap between clinical trial populations and real-world patients by including a broader patient group treated in general practice. Participants will be followed prospectively from their initial diagnosis until death. Data collection includes medical history, clinical parameters, imaging, pathology, tumor details, treatments, hospital stays, interventions, and adverse events. With separate consent, patient-reported quality of life and work ability information will also be gathered. Additionally, biological samples obtained during routine care may be collected for further observational and molecular research. This cohort serves as a platform for evaluating new interventions through a Trials within Cohorts TwiCs design. Throughout up to ten years of follow-up, participants will undergo assessments of progression-free survival, disease-free survival, overall survival, and serious adverse events. Quality of life and work ability are assessed at intervals of 3, 6, 12, 24, 36, and 48 months. This extensive data collection supports a wide range of research aims including prognostic studies, molecular analyses, comparisons of new treatments, and health policy evaluations. The study provides a comprehensive view of treatment outcomes and patient experiences in everyday clinical settings.
Actively Recruiting
Researchers are evaluating the effects of etripamil nasal spray NS compared to placebo in patients who have atrial fibrillation AF with rapid ventricular rate RVR. This is a multi-national, multi-center, randomized, double-blind, placebo-controlled phase 3 study aiming to assess how well etripamil works in this condition. The study includes several phases such as screening, randomization, treatment, follow-up visits, a final study visit, and a telephone follow-up at the end. Participants are randomly assigned to receive either placebo or 70 mg of etripamil NS. They will self-administer the study drug during episodes of AF with RVR, starting with an initial dose and possibly a second dose 10 minutes later if symptoms continue. Patients may treat up to four episodes during the study. The study drug is given as a nasal spray, and the placebo formulation is designed to match the pH of the active drug. Participants will be involved in screening procedures including physical exams, vital signs, ECGs, and lab tests. During the treatment period, they will use ECG cardiac monitoring devices and report symptoms electronically. Monthly follow-up visits and post-treatment visits will monitor safety, collect information on any additional medical interventions, and ensure ongoing eligibility. The final study visit and a telephone follow-up approximately 30 days later will complete the study monitoring. The primary outcome is to measure the efficacy of etripamil within 30 minutes of the first dose.
Actively Recruiting
Researchers are studying the effect of at-home taste steering compared to standard care on food enjoyment in patients with metastatic triple negative breast cancer, metastatic testicular cancer, or stage II-IV diffuse large B cell lymphoma who are undergoing chemotherapy. This multicentre randomized intervention trial uses a parallel cluster design across 12 hospitals in the Netherlands to prevent bias from patient contact within the same hospital. The study measures outcomes before chemotherapy begins, at the onset of taste or smell alterations, and after 6 weeks. Participants in the experimental group will use taste steering techniques at home while the control group receives usual care. Questionnaires are completed online from home, and taste and smell tests plus saliva collection are done either at home or during regular hospital visits. Both groups will have contact with their dietitian every 3 weeks. The intervention lasts 6 weeks, based on prior experience indicating the taste steering algorithm saturates after 3-4 weeks. During the study, participants will complete assessments of food enjoyment, health-related quality of life, taste and smell function, saliva secretion, and body weight. These are measured at baseline, at the time taste or smell changes occur, and after 6 weeks. Researchers will also monitor risk of malnutrition and dry mouth feeling. The total participation period covers the 6-week intervention and associated follow-up assessments.
Actively Recruiting
Researchers are evaluating the impact of at-home taste and smell training compared to standard care in patients with cancer treated with tyrosine kinase inhibitors. This multicenter randomized intervention trial involves 12 hospitals in the Netherlands and aims to understand how this training affects taste function and other related outcomes over 12 weeks. The study uses a parallel cluster design to avoid bias by keeping treatment groups separate within each hospital. Participants are assigned to either perform taste and smell training at home or receive usual care without the training. Measurements are taken at baseline and after 12 weeks, including taste and smell tests, saliva collection, and online questionnaires completed at home. Dietitians contact patients every 3 weeks in both groups to support adherence and monitor progress. During the study, participants undergo assessments of taste and smell function, food enjoyment, quality of life, risk of malnutrition, dry mouth sensation, saliva secretion, and body weight. These evaluations occur at home or during regular hospital visits. The total duration for each participant is approximately 12 weeks, during which researchers track changes and safety related to the interventions.